Alma vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health network connecting clients to in-network therapists; handles credentialing, billing, and insurance contracting for affiliated clinicians; one of largest US therapist networks.
About
Alma is a New York-based mental health company that operates a network of therapists and psychiatrists, providing them with the business infrastructure to run private practices while accepting insurance. Alma handles credentialing, billing, insurance contracting, and administrative tasks for affiliated clinicians, enabling therapists to focus on patient care rather than paperwork while earning more than they could through employment at a group practice. On the patient side, Alma makes it easier to find available in-network therapists — a persistent challenge in mental healthcare — through its searchable directory of affiliated providers across the country. Alma has built one of the largest networks of private practice therapists accepting insurance in the United States, with thousands of clinicians across most states. Founded in 2017, Alma raised over $220M from investors including Insight Partners, Tiger Global, and Optum Ventures. The company addresses both sides of the mental health access crisis: insufficient supply of providers and inadequate insurance reimbursement making private practice financially unviable.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.